Q1 2021

Filed May 13, 2021 · 10-Q · 43 days after period end · 0001826466-21-000097

Q1 2021 · 10-Q

Revenue—

Net Income

-$5.75K

no prior Q1 2020 on file

EPS Diluted

$0.00

no prior Q1 2020 on file

Operating Income-$5,754—

Operating Cash Flow-$5,754—

Same quarter

no prior Q1 2020 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end

Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR